Yifan Xinfu Pharmaceutical Co Ltd

SHE:002019 China Drug Manufacturers - General
Market Cap
$2.32 Billion
CN¥17.01 Billion CNY
Market Cap Rank
#7304 Global
#1227 in China
Share Price
CN¥13.98
Change (1 day)
-2.37%
52-Week Range
CN¥10.48 - CN¥16.29
All Time High
CN¥32.51
Categories
Companies in China Drug Manufacturers - General
About

Yifan Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products, raw materials, and polymer materials in Southeast Asia, Europe and North America, Singapore, South Korea, Italy, China, Germany, and the United States. It offers Chinese patent medicines, chemical medicines and biological medicines; and vitamin products, including vitamin B5 an… Read more

Yifan Xinfu Pharmaceutical Co Ltd (002019) - Net Assets

Latest net assets as of September 2025: CN¥8.71 Billion CNY

Based on the latest financial reports, Yifan Xinfu Pharmaceutical Co Ltd (002019) has net assets worth CN¥8.71 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥13.11 Billion) and total liabilities (CN¥4.40 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥8.71 Billion
% of Total Assets 66.45%
Annual Growth Rate 24.73%
5-Year Change -3.48%
10-Year Change 192.54%
Growth Volatility 92.32

Yifan Xinfu Pharmaceutical Co Ltd - Net Assets Trend (2001–2024)

This chart illustrates how Yifan Xinfu Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Yifan Xinfu Pharmaceutical Co Ltd (2001–2024)

The table below shows the annual net assets of Yifan Xinfu Pharmaceutical Co Ltd from 2001 to 2024.

Year Net Assets Change
2024-12-31 CN¥8.43 Billion +2.08%
2023-12-31 CN¥8.25 Billion -9.75%
2022-12-31 CN¥9.15 Billion +4.24%
2021-12-31 CN¥8.77 Billion +0.51%
2020-12-31 CN¥8.73 Billion +11.62%
2019-12-31 CN¥7.82 Billion +13.56%
2018-12-31 CN¥6.89 Billion +1.55%
2017-12-31 CN¥6.78 Billion +73.88%
2016-12-31 CN¥3.90 Billion +35.41%
2015-12-31 CN¥2.88 Billion +13.25%
2014-12-31 CN¥2.54 Billion +401.03%
2013-12-31 CN¥507.64 Million +5.58%
2012-12-31 CN¥480.81 Million +2.41%
2011-12-31 CN¥469.52 Million -33.27%
2010-12-31 CN¥703.64 Million -22.94%
2009-12-31 CN¥913.15 Million +59.96%
2008-12-31 CN¥570.87 Million +4.07%
2007-12-31 CN¥548.55 Million +74.45%
2006-12-31 CN¥314.44 Million -2.02%
2005-12-31 CN¥320.93 Million +3.53%
2004-12-31 CN¥309.98 Million +228.68%
2003-12-31 CN¥94.31 Million +18.73%
2002-12-31 CN¥79.43 Million +51.84%
2001-12-31 CN¥52.31 Million --

Equity Component Analysis

This analysis shows how different components contribute to Yifan Xinfu Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 17261.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥4.47 Billion 52.43%
Common Stock CN¥1.04 Billion 12.16%
Other Components CN¥3.02 Billion 35.40%
Total Equity CN¥8.52 Billion 100.00%

Yifan Xinfu Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Yifan Xinfu Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
Universal Robina Corporation
PINK:UVRBF
 		$1.01 Billion
Partner Communications Company Ltd.
PINK:PTNRF
 		$1.01 Billion
Grupo Gigante S. A. B. de C. V
PINK:GPGNF
 		$1.01 Billion
Aarti Industries Limited
NSE:AARTIIND
 		$1.01 Billion
IMMUNOCORE HLDGS ADS/1
F:6YG
 		$1.01 Billion
Vizio Holding Corp
NYSE:VZIO
 		$1.01 Billion
Alliance Financial Group Bhd
KLSE:2488
 		$1.01 Billion
Shenzhen United Winners Laser Co Ltd
SHG:688518
 		$1.01 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Yifan Xinfu Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 8,275,633,622 to 8,521,867,867, a change of 246,234,245 (3.0%).
  • Net income of 385,967,575 contributed positively to equity growth.
  • Dividend payments of 194,813,094 reduced retained earnings.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥385.97 Million +4.53%
Dividends Paid CN¥194.81 Million -2.29%
Other Changes CN¥55.08 Million +0.65%
Total Change CN¥- 2.98%

Book Value vs Market Value Analysis

This analysis compares Yifan Xinfu Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.98x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 127.36x to 1.98x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2001-12-31 CN¥0.11 CN¥13.98 x
2002-12-31 CN¥0.17 CN¥13.98 x
2003-12-31 CN¥0.20 CN¥13.98 x
2004-12-31 CN¥0.65 CN¥13.98 x
2005-12-31 CN¥0.67 CN¥13.98 x
2006-12-31 CN¥0.72 CN¥13.98 x
2007-12-31 CN¥1.15 CN¥13.98 x
2008-12-31 CN¥1.22 CN¥13.98 x
2009-12-31 CN¥1.80 CN¥13.98 x
2010-12-31 CN¥1.26 CN¥13.98 x
2011-12-31 CN¥0.84 CN¥13.98 x
2012-12-31 CN¥0.87 CN¥13.98 x
2013-12-31 CN¥0.93 CN¥13.98 x
2014-12-31 CN¥3.72 CN¥13.98 x
2015-12-31 CN¥2.62 CN¥13.98 x
2016-12-31 CN¥3.20 CN¥13.98 x
2017-12-31 CN¥5.70 CN¥13.98 x
2018-12-31 CN¥5.48 CN¥13.98 x
2019-12-31 CN¥6.14 CN¥13.98 x
2020-12-31 CN¥6.89 CN¥13.98 x
2021-12-31 CN¥7.05 CN¥13.98 x
2022-12-31 CN¥6.91 CN¥13.98 x
2023-12-31 CN¥6.76 CN¥13.98 x
2024-12-31 CN¥7.07 CN¥13.98 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Yifan Xinfu Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 4.53%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 7.48%
  • • Asset Turnover: 0.42x
  • • Equity Multiplier: 1.44x
  • Recent ROE (4.53%) is below the historical average (9.58%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2001 47.26% 27.07% 1.05x 1.67x CN¥19.49 Million
2002 32.82% 19.91% 0.99x 1.66x CN¥18.12 Million
2003 27.44% 14.64% 0.89x 2.11x CN¥16.45 Million
2004 10.49% 13.27% 0.68x 1.16x CN¥1.52 Million
2005 6.40% 7.60% 0.52x 1.62x CN¥-11.53 Million
2006 2.78% 2.52% 0.59x 1.85x CN¥-22.71 Million
2007 43.79% 31.41% 0.86x 1.61x CN¥185.33 Million
2008 7.22% 8.59% 0.56x 1.50x CN¥-15.85 Million
2009 3.33% 7.48% 0.36x 1.25x CN¥-60.95 Million
2010 -28.40% -52.00% 0.32x 1.73x CN¥-267.11 Million
2011 -49.36% -46.45% 0.43x 2.50x CN¥-276.94 Million
2012 2.98% 2.22% 0.61x 2.21x CN¥-33.76 Million
2013 23.17% 10.16% 1.09x 2.09x CN¥66.88 Million
2014 9.35% 14.12% 0.51x 1.31x CN¥-16.51 Million
2015 12.62% 14.81% 0.54x 1.59x CN¥74.77 Million
2016 20.00% 20.11% 0.50x 1.98x CN¥352.30 Million
2017 20.18% 29.84% 0.50x 1.36x CN¥658.25 Million
2018 11.13% 15.92% 0.47x 1.48x CN¥75.04 Million
2019 12.05% 17.42% 0.47x 1.48x CN¥153.51 Million
2020 11.47% 17.93% 0.46x 1.38x CN¥124.40 Million
2021 3.26% 6.31% 0.36x 1.43x CN¥-575.12 Million
2022 2.17% 4.98% 0.31x 1.42x CN¥-689.93 Million
2023 -6.66% -13.55% 0.35x 1.39x CN¥-1.38 Billion
2024 4.53% 7.48% 0.42x 1.44x CN¥-466.22 Million

Industry Comparison

This section compares Yifan Xinfu Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.

Industry Context

  • Industry: Drug Manufacturers - General
  • Average net assets among peers: $825,675,741
  • Average return on equity (ROE) among peers: 5.53%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Yifan Xinfu Pharmaceutical Co Ltd (002019) CN¥8.71 Billion 47.26% 0.50x $1.01 Billion
Zhejiang Int'L Group Co Ltd (000411) $189.44 Million 3.08% 4.33x $199.04 Million
Zhejiang Zhenyuan Share Co Ltd (000705) $485.74 Million 1.60% 0.77x $307.06 Million
Hunan Jingfeng Pharmaceutical (000908) $336.40 Million 0.81% 1.44x $202.85 Million
Hubei Guangji Pharmaceutical Co Ltd (000952) $1.49 Billion 3.37% 0.66x $229.65 Million
Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) $1.25 Billion 8.38% 0.07x $144.69 Million
Guangdong Jiaying Pharmaceutical Co Ltd (002198) $226.35 Million 6.06% 0.04x $447.60 Million
Chongqing Lummy Pharmaceutical (300006) $1.88 Billion -4.66% 0.52x $475.43 Million
Zhejiang Jolly Pharmaceutical Co Ltd (300181) $1.39 Billion 1.50% 0.52x $1.19 Billion
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) $181.38 Million 29.65% 0.05x $893.83 Million